SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (15175)2/17/1998 12:23:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
Andy, LGND's cheat sheet (linked to Research Magazine in home.att.net ) shows Actinic Keratosis under potential markets (1.5 million cases) for Targretin, but I'm not sure about the specific clinicals for that indication (but I seem to remember it being in Phase II, so I suspect that there is some initial data). I haven't seen any skin cancer (other than CTCL or KS which are cancers that present externally), but obviously, LGND could attack the problem with gel or oral formulations.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext